RESUMO
Antecedentes y objetivo: En España, más del 10% de los pacientes con insuficiencia cardíaca aguda (ICA) dados de alta son reingresados en los primeros 30 días. Se diseña este trabajo para valorar si el tratamiento dela ICA guiado por ecografía clínica (EC) en el ámbito de hospitalización a domicilio (HAD) reduce la incidencia de reingreso y mortalidad respecto al abordaje estándar (AE).Pacientes y métodosSe diseñó un ensayo clínico aleatorizado (ECA), abierto, paralelo, unicéntrico y controlado (NT05042752). Se incluyeron de forma consecutiva a pacientes>18 años ingresados por ICA en HAD desde enero del 2021 hasta abril del 2021 en el Hospital Reina Sofía de Tudela. Los pacientes se aleatorizaron a «grupo ecografía (GE)» (realización de AE y EC) y «grupo control (GC)» (AE). El tratamiento diurético fue modificado según los hallazgos del AE junto con la EC o según los hallazgos del AE, respectivamente. Las variables principales fueron el riesgo relativo (RR) de reingreso y mortalidad por ICA.ResultadosUn total de 79 pacientes fueron aleatorizados, 39 a GE y 40 a GC. De ellos, solo completaron la intervención 35 del GC y 35 del GE. El riesgo de reingreso por ICA se redujo un 60% en el GE respecto del GC (RR 0,4; IC del 95%: 0,1-1) y el de mortalidad en un 30% (RR 0,7; IC del 95%: 0,2-2,2). A pesar de la relevante magnitud del efecto encontrado, los resultados no alcanzan la significación estadística por falta de potencia.ConclusiónNuestros resultados sugieren que en HAD, el tratamiento de la ICA guiado por EC podría reducir el riesgo de reingreso y mortalidad respecto al AE, aunque hacen falta estudios con mayor potencia estadística que confirmen estos resultados. (AU)
Background and objective: In Spain, more than 10% of patients discharged with acute heart failure (AHF) are readmitted in the first 30 days. This study is designed to assess whether the treatment of AHF guided by clinical ultrasound (CU) in the setting of hospitalization at home (HAH) reduces the incidence of readmission and mortality compared to the standard care (SC).Patients and methodsA randomized, open, parallel, single-center and controlled clinical trial (RCT) was designed (NT05042752). Patients >18 years of age admitted for AHF to HAD from January 2021 to April 2021 at the Reina Sofía Hospital in Tudela were consecutively included. The patients were randomized to the UG-ultrasound group (SC and CU performed) and the CG-control group (SC). The diuretic treatment was tailored according to the findings of the SC together with the CU or according to the findings of the SC respectively. The main variables were the relative risk of readmission and mortality from AHF.ResultsA total of 79 patients were randomized, 39 to UG and 40 to CG. Of these, only 35 of the UG and 35 of the CG completed the intervention. The risk of readmission due to AHF was reduced by 60% in UG compared to CG (RR 0.4; 95% CI: 0.11) and mortality by 30% (RR 0.7; 95% CI: 0.22.2). Despite the relevant magnitude of the effect found, the results did not reach statistical significance due to lack of power.ConclusionOur results suggest that in HAH, a CE guided strategy for AHF could reduce the risk of readmission and mortality compared to SC alone. However, studies with greater statistical power are needed to confirm these results. (AU)
Assuntos
Humanos , Doença Aguda , Cobre , Insuficiência Cardíaca/tratamento farmacológico , Insuficiência Cardíaca/terapia , Hospitalização , Alta do PacienteRESUMO
Background and objectives: The efficacy and safety of ustekinumab have been proved in clinical trials. In daily clinical practice, knowing the factors that determine survival differences of biological drugs allows psoriasis treatment to be optimized as a function of patient characteristics. The main objectives of this work are to understand ustekinumab drug survival in patients diagnosed with plaque psoriasis in the Hospital Universitario Central de Asturias (HUCA Dermatology Department, and to identify the predictors of drug discontinuation. Materials and Methods: A retrospective hospital-based study, including data from 148 patients who were receiving ustekinumab (Stelara®) between 1 February 2009 and 30 November 2019, were collected. Survival curves were approximated through the Kaplan-Meier estimator and compared using the log-rank test. Proportional hazard Cox regression models were used for multivariate analyses while both unadjusted and adjusted hazard ratios (HR) were used for summarizing the studied differences. Results: The average duration of the treatment before discontinuation was 47.57 months (SD 32.63 months; median 41 months). The retention rates were 82% (2 years), 66% (5 years), and 58% (8 years). Median survival was 80 months (95% confidence interval. CI 36.9 to 123.01 months). The survival study revealed statistically significant differences between patients with arthritis (log-rank test, p < 0.001) and those who had previously received biological treatment (log-rank test, p = 0.026). The five-year prevalence in patients still under treatment was 80% (those without arthritis) and 54% (arthritis patients). In the multivariate analysis, only the patients with arthritis had a lower rate of drug survival. No statistically significant differences were observed for any of the other comorbidities studied. The first and second most frequent causes of discontinuation were secondary failure and arthritis inefficacy, respectively. Conclusion: Ustekinumab is a biological drug conferring high survival in plaque psoriasis patients. Ustekinumab survival is lower in patients with arthritis.
Assuntos
Preparações Farmacêuticas , Psoríase , Adalimumab , Humanos , Psoríase/tratamento farmacológico , Estudos Retrospectivos , Resultado do Tratamento , Ustekinumab/uso terapêuticoRESUMO
No disponible
